CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Policy governs coverage determinations for saturation biopsy (generally >20 cores, transrectal or transperineal stereotactic template-guided) when used for diagnosis, repeat biopsy, staging, or management (including active surveillance) of prostate cancer for Medicare Advantage and Commercial products from Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicySaturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeClarified (coding guidance)

Effective Date

Next Review Date

Key ActionDo not file claims for saturation biopsy with CPT 55700 (deleted 12/31/2025) or G0416; bill appropriately and note that CPT 55706 is not covered/considered not medically necessary.

POLICY UPDATE CHANGES

Guidance that claims should not be filed with codes 55700 (Code Deleted Effective 12/31/2025) or G0416 when performing saturation biopsy.

1Primary coverage stance (not covered)

1Specific CPT code called out as not covered

NoMaterial change

Coverage Summary

Scope: This policy governs coverage determinations for saturation prostate biopsy used for diagnosis, repeat biopsy, staging, or management (including active surveillance) of prostate cancer. The policy applies to procedures generally defined as obtaining more than 20 cores from the prostate and may include transrectal or transperineal (stereotactic template-guided) approaches.

Policy facts

Policy scope/governsCoverage determinations for saturation biopsy (generally >20 cores, transrectal or transperineal stereotactic template-guided) when used for diagnosis, repeat biopsy, staging, or management (including active surveillance) of prostate cancer for Medicare Advantage and Commercial products

Primary stanceNot Covered / Not Medically Necessary for saturation biopsy

Affected productsMedicare Advantage Plans and Commercial Products

Key CPT code statusCPT 55706 (transperineal stereotactic template guided saturation sampling) is not covered / not medically necessary; do not file claims for saturation biopsy with CPT 55700 (deleted 12/31/2025) or G0416

Saturation biopsy definitionGenerally more than 20 cores taken from the prostate

Medical-Necessity Criteria

Coverage Determination - Medicare Advantage Plans

Saturation biopsy is covered only when criteria are met (policy states not covered):

Saturation biopsy is not covered in the diagnosis, staging, and management of prostate cancer because the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

Coverage Determination - Commercial Products

Saturation biopsy coverage for commercial members:

Saturation biopsy is considered not medically necessary in the diagnosis, staging, and management of prostate cancer because the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

Coding and Claims Guidance

CPT code 55706 is not covered for Medicare Advantage Plans and not medically necessary for Commercial Products: '55706 Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance'.

When performing saturation biopsy, claims should not be filed with codes 55700 (Code Deleted Effective 12/31/2025) or G0416, as these are not specific to saturation sampling.

55700 deleted effective 12/31/2025

Not covered / Not medically necessary (Saturation biopsy)CPTNot Covered

55706

Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance

Codes not to be used for saturation biopsy claimsmixedNot Covered

55700	Code Deleted Effective 12/31/2025
G0416	Not specific to saturation sampling

Provider Actions

Documentation Required

Do not bill unsupported codes for saturation biopsy

Claims for saturation biopsy should be billed using appropriate codes; do not file claims for saturation biopsy with CPT 55700 (Code Deleted Effective 12/31/2025) or G0416 as these are not specific to saturation sampling.

55706
55700
G0416
Do not file claims with CPT 55700 or G0416 for saturation biopsy

Denial Risk

Claim denial / not medically necessary risk

Saturation biopsy (CPT 55706) is not covered under Medicare Advantage and is considered not medically necessary for Commercial products — claims may be denied.

55706
Claims may be denied for Medicare Advantage and Commercial products

Background & Evidence Summary

Background: Saturation biopsy involves obtaining more cores than standard biopsy protocols (generally >20 cores) to improve sampling of anterior zones and reduce missed cancers. It may be performed transrectally or via a transperineal, stereotactic template-guided approach (often with general anesthesia).

Evidence gap: Although randomized trials, observational studies, and systematic reviews report higher cancer detection rates in some settings (especially repeat biopsy), the literature does not demonstrate improved health outcomes such as progression or survival; some detected cancers may be clinically insignificant. As a result, saturation biopsy has not been shown to improve net health outcomes.

Evidence	Summary
Systematic review (2013)
Found higher detection rates with saturation versus extended biopsy overall; in men with PSA <10 ng/mL the difference was small and possibly not clinically significant; health outcomes (eg, survival) were not reported.
Repeat biopsy studies
Observational studies and reviews show higher cancer detection rates with saturation biopsy on repeat biopsy, but about one-third of positive findings may be clinically insignificant and studies did not report progression or survival outcomes.
Active surveillance comparative studies
Two nonrandomized comparative studies did not find that saturation biopsy improved selection for active surveillance; biopsy method was not a significant predictor of upstaging or of selecting patients with high Gleason score.

Definitions

Saturation biopsyAn approach generally defined as more than 20 cores taken from the prostate with improved sampling of anterior zones; may be transrectal or transperineal (stereotactic template-guided).

Extended biopsyCommon initial biopsy strategy using approximately 12 to 14 cores to sample lateral peripheral zone.

Revision History

12/31/2025code_deletion

Guidance notes that CPT code 55700 is deleted effective 12/31/2025; providers should not file claims for saturation biopsy using 55700.

currentclaims_instructionLatest

Instruction that claims for saturation biopsy should not be filed with codes 55700 (Code Deleted Effective 12/31/2025) or G0416, as these codes are not specific to saturation sampling.